2022 Progress Report
Increasing the Impact of Data Sharing

Dear Friends,

As we close out 2022, the role that data sharing plays in furthering science has never been clearer. I am humbled to see how so many researchers are using Vivli to extract important new insights from the raw data that underpins clinical trials. Their discoveries are shaping new patient decision-making tools, clinical guidelines, trial protocols and other solutions that have a real-world impact.

Just this year, we had more than 84 public disclosures from investigators across the globe who are using data on the Vivli platform to answer new research questions. To date, we’ve approved more than 300 proposals that span a breadth of health conditions, from diseases that are the leading causes of death such as cancer and cardiovascular disease, to those that are increasingly drawing attention after recent national and global crises, such as mental health and infectious diseases, including coronavirus.

Our impact wouldn’t be possible without the companies and institutions that have stepped up to share their data and put their trust in Vivli. We now have almost 7,000 trials in our inventory, contributed by our 45 members. This year, we welcomed Bayer, Ipsen, Sanofi and Sunovion SMP as members, as well as the NIH HEAL Initiative and the National Institute of Diabetes and Digestive and Kidney Disease Central Repository (NIDDK CR-R4R). We also launched new collaborations with The Leona M. and Harry B. Helmsley Charitable Trust to host a data challenge with the aim to drive type 1 diabetes and exercise data to solutions, as well as the NIH Office of Data Science Strategy to improve access and discoverability of NIH-funded data.

2023 will mark five years since the launch of Vivli. As we move towards this milestone, we look forward to welcoming even more researchers to contribute data into our platform as the NIH Data Management and Sharing Policy comes into effect, and to hosting new data challenges and forming novel partnerships to stimulate even more research that maximizes the value of clinical trial data.

As I reflect on how far we’ve come and what lies ahead, I’m so grateful for partners and leaders like you. Thank you for all you do.




2022 Highlights

Launch of the AMR register Read more
Antimicrobial resistance (AMR) is a growing threat to health and lives around the world. One way to address this growing, silent pandemic is to share surveillance data among the scientific community. In June, Vivli launched the AMR Data Register to accomplish just this, making it possible for biopharmaceutical companies to share data on infection-causing pathogens for the first time on an online platform.
Analyzing COVID-19 data sharing Read more
When COVID-19 hit, the scientific community responded promptly to develop treatments and vaccines, and pledged to share their data to accelerate research. To see whether the community lived up to its data sharing promise, Vivli analyzed data from ClinicalTrials.gov, finding that declared intentions to share COVID-19 clinical trial data grew from 21.4% to 57% over the first 18 months of the pandemic.
T1 Diabetes data challenge Read more
Exercising while having type 1 diabetes is challenging, and even unsafe without proper preparation for activity. The Leona M. and Harry B. Helmsley Charitable Trust contributed data collected from constant glucose monitors to Vivli and launched a unique challenge to researchers to use this data to help people with type 1 diabetes manage their physical activity and live healthy, active lives.
2022 Annual Meeting Read more
In November 2022, data contributors, collaborators, and funders from across the world joined Vivli for a robust discussion on data sharing and its importance to further scientific discoveries. On top of everyone’s mind were best practices for sharing COVID-19 clinical trial data and the NIH data sharing policy changes that will take effect in 2023.

2022 Milestones

2022 Milestones

2022 Revenue and Expenses


2022 Revenue


2020 Expenses